BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ganguly SS, Fiore LS, Sims JT, Friend JW, Srinivasan D, Thacker MA, Cibull ML, Wang C, Novak M, Kaetzel DM, Plattner R. c-Abl and Arg are activated in human primary melanomas, promote melanoma cell invasion via distinct pathways, and drive metastatic progression. Oncogene 2012;31:1804-16. [PMID: 21892207 DOI: 10.1038/onc.2011.361] [Cited by in Crossref: 43] [Cited by in F6Publishing: 52] [Article Influence: 3.9] [Reference Citation Analysis]
Number Citing Articles
1 Lan F, Chen X, Xiong Z, Cao Z, Lu L, Zhong Y, Zhan X, Yang Y, Shao Y, Li M, Han Z, Zhu X. Comprehensive transcriptomic and co-expression analysis of ABL1 gene and molecularly targeted drugs in hepatocellular carcinoma based on multi-database mining. Med Oncol 2022;39:146. [PMID: 35834027 DOI: 10.1007/s12032-022-01730-y] [Reference Citation Analysis]
2 Liu H, Gao H, Chen C, Jia W, Xu D, Jiang G. IDO Inhibitor and Gallic Acid Cross-Linked Small Molecule Drug Synergistic Treatment of Melanoma. Front Oncol 2022;12:904229. [DOI: 10.3389/fonc.2022.904229] [Reference Citation Analysis]
3 Wu K, Wu H, Lyu W, Kim Y, Furdui CM, Anderson KS, Koleske AJ. Platelet-derived growth factor receptor beta activates Abl2 via direct binding and phosphorylation. J Biol Chem 2021;297:100883. [PMID: 34144039 DOI: 10.1016/j.jbc.2021.100883] [Reference Citation Analysis]
4 Choo F, Rakheja D, Davis LE, Davare M, Park JY, Timmons CF, Neff T, Beadling C, Corless CL, Davis JL. GAB1-ABL1 fusions in tumors that have histologic overlap with NTRK-rearranged spindle cell tumors. Genes Chromosomes Cancer 2021;60:623-30. [PMID: 34036664 DOI: 10.1002/gcc.22972] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
5 Luttman JH, Colemon A, Mayro B, Pendergast AM. Role of the ABL tyrosine kinases in the epithelial-mesenchymal transition and the metastatic cascade. Cell Commun Signal 2021;19:59. [PMID: 34022881 DOI: 10.1186/s12964-021-00739-6] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
6 Tripathi R, Liu Z, Jain A, Lyon A, Meeks C, Richards D, Liu J, He D, Wang C, Nespi M, Rymar A, Wang P, Wilson M, Plattner R. Combating acquired resistance to MAPK inhibitors in melanoma by targeting Abl1/2-mediated reactivation of MEK/ERK/MYC signaling. Nat Commun 2020;11:5463. [PMID: 33122628 DOI: 10.1038/s41467-020-19075-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
7 Balaji Ragunathrao VA, Anwar M, Akhter MZ, Chavez A, Mao Y, Natarajan V, Lakshmikanthan S, Chrzanowska-Wodnicka M, Dudek AZ, Claesson-Welsh L, Kitajewski JK, Wary KK, Malik AB, Mehta D. Sphingosine-1-Phosphate Receptor 1 Activity Promotes Tumor Growth by Amplifying VEGF-VEGFR2 Angiogenic Signaling. Cell Rep 2019;29:3472-3487.e4. [PMID: 31825830 DOI: 10.1016/j.celrep.2019.11.036] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 8.0] [Reference Citation Analysis]
8 Rizzo AN, Belvitch P, Demeritte R, Garcia JGN, Letsiou E, Dudek SM. Arg mediates LPS-induced disruption of the pulmonary endothelial barrier. Vascul Pharmacol 2020;128-129:106677. [PMID: 32240815 DOI: 10.1016/j.vph.2020.106677] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
9 Tan FH, Putoczki TL, Stylli SS, Luwor RB. Ponatinib: a novel multi-tyrosine kinase inhibitor against human malignancies. Onco Targets Ther 2019;12:635-45. [PMID: 30705592 DOI: 10.2147/OTT.S189391] [Cited by in Crossref: 55] [Cited by in F6Publishing: 66] [Article Influence: 18.3] [Reference Citation Analysis]
10 He C, Plattner R, Rangnekar V, Zhou B, Liu C, Stewart RL, Huang B, Wang C, Tucker TC. Potential protein markers for breast cancer recurrence: a retrospective cohort study. Cancer Causes Control 2019;30:41-51. [PMID: 30488343 DOI: 10.1007/s10552-018-1099-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
11 Tripathi R, Plattner R. EnABLing Cathepsin-Driven Melanoma Metastasis. Mol Cell Oncol 2018;5:e1458016. [PMID: 30250913 DOI: 10.1080/23723556.2018.1458016] [Reference Citation Analysis]
12 Feng R, Wang X, Li J, Chen K, Guo G, Liao Y, Sun L, Huang S, Chen JL. Interaction of Abl Tyrosine Kinases with SOCS3 Impairs Its Suppressor Function in Tumorigenesis. Neoplasia 2018;20:1095-105. [PMID: 30236924 DOI: 10.1016/j.neo.2018.09.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
13 Peng X, Wang Z, Liu Y, Peng X, Liu Y, Zhu S, Zhang Z, Qiu Y, Jin M, Wang R, Zhang Q, Kong D. Oxyfadichalcone C inhibits melanoma A375 cell proliferation and metastasis via suppressing PI3K/Akt and MAPK/ERK pathways. Life Sciences 2018;206:35-44. [DOI: 10.1016/j.lfs.2018.05.032] [Cited by in Crossref: 13] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
14 Tripathi R, Liu Z, Plattner R. EnABLing Tumor Growth and Progression: Recent progress in unraveling the functions of ABL kinases in solid tumor cells. Curr Pharmacol Rep 2018;4:367-79. [PMID: 30746323 DOI: 10.1007/s40495-018-0149-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
15 Meirson T, Genna A, Lukic N, Makhnii T, Alter J, Sharma VP, Wang Y, Samson AO, Condeelis JS, Gil-Henn H. Targeting invadopodia-mediated breast cancer metastasis by using ABL kinase inhibitors. Oncotarget 2018;9:22158-83. [PMID: 29774130 DOI: 10.18632/oncotarget.25243] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 4.3] [Reference Citation Analysis]
16 Silveira E, Cavalcante IP, Kremer JL, de Mendonça POR, Lotfi CFP. The tyrosine kinase inhibitor nilotinib is more efficient than mitotane in decreasing cell viability in spheroids prepared from adrenocortical carcinoma cells. Cancer Cell Int 2018;18:29. [PMID: 29507530 DOI: 10.1186/s12935-018-0527-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
17 Lamballe F, Toscano S, Conti F, Arechederra M, Baeza N, Figarella-Branger D, Helmbacher F, Maina F. Coordination of signalling networks and tumorigenic properties by ABL in glioblastoma cells. Oncotarget 2016;7:74747-67. [PMID: 27732969 DOI: 10.18632/oncotarget.12546] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
18 Tripathi R, Fiore LS, Richards DL, Yang Y, Liu J, Wang C, Plattner R. Abl and Arg mediate cysteine cathepsin secretion to facilitate melanoma invasion and metastasis. Sci Signal 2018;11:eaao0422. [PMID: 29463776 DOI: 10.1126/scisignal.aao0422] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 4.5] [Reference Citation Analysis]
19 Leonard MK, McCorkle JR, Snyder DE, Novak M, Zhang Q, Shetty AC, Mahurkar AA, Kaetzel DM. Identification of a gene expression signature associated with the metastasis suppressor function of NME1: prognostic value in human melanoma. Lab Invest 2018;98:327-38. [PMID: 29058705 DOI: 10.1038/labinvest.2017.108] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
20 Saleh T, Rossi P, Kalodimos CG. Atomic view of the energy landscape in the allosteric regulation of Abl kinase. Nat Struct Mol Biol 2017;24:893-901. [PMID: 28945248 DOI: 10.1038/nsmb.3470] [Cited by in Crossref: 35] [Cited by in F6Publishing: 38] [Article Influence: 7.0] [Reference Citation Analysis]
21 Kazi JU, Rupar K, Marhäll A, Moharram SA, Khanum F, Shah K, Gazi M, Nagaraj SR, Sun J, Chougule RA, Rönnstrand L. ABL2 suppresses FLT3-ITD-induced cell proliferation through negative regulation of AKT signaling. Oncotarget 2017;8:12194-202. [PMID: 28086240 DOI: 10.18632/oncotarget.14577] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
22 Dong Q, Li C, Qu X, Cao C, Liu X. Global Regulation of Differential Gene Expression by c-Abl/Arg Oncogenic Kinases. Med Sci Monit 2017;23:2625-35. [PMID: 28555614 DOI: 10.12659/msm.904888] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
23 Yokota A, Hirai H, Shoji T, Maekawa T, Okuda K. Constitutively active ABL family kinases, TEL/ABL and TEL/ARG, harbor distinct leukemogenic activities in vivo. Leukemia 2017;31:2742-51. [PMID: 28386107 DOI: 10.1038/leu.2017.114] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
24 Jain A, Tripathi R, Turpin CP, Wang C, Plattner R. Abl kinase regulation by BRAF/ERK and cooperation with Akt in melanoma. Oncogene 2017;36:4585-96. [PMID: 28368422 DOI: 10.1038/onc.2017.76] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
25 Khera L, Paul C, Kaul R. Hepatitis C Virus E1 protein promotes cell migration and invasion by modulating cellular metastasis suppressor Nm23-H1. Virology 2017;506:110-20. [PMID: 28376369 DOI: 10.1016/j.virol.2017.03.014] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
26 Mahas A, Potluri K, Kent MN, Naik S, Markey M. Copy number variation in archival melanoma biopsies versus benign melanocytic lesions. Cancer Biomark 2016;16:575-97. [PMID: 27002761 DOI: 10.3233/CBM-160600] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
27 Testoni E, Stephenson NL, Torres-Ayuso P, Marusiak AA, Trotter EW, Hudson A, Hodgkinson CL, Morrow CJ, Dive C, Brognard J. Somatically mutated ABL1 is an actionable and essential NSCLC survival gene. EMBO Mol Med 2016;8:105-16. [PMID: 26758680 DOI: 10.15252/emmm.201505456] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
28 Varzavand A, Hacker W, Ma D, Gibson-Corley K, Hawayek M, Tayh OJ, Brown JA, Henry MD, Stipp CS. α3β1 Integrin Suppresses Prostate Cancer Metastasis via Regulation of the Hippo Pathway. Cancer Res 2016;76:6577-87. [PMID: 27680681 DOI: 10.1158/0008-5472.CAN-16-1483] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 4.8] [Reference Citation Analysis]
29 Wang J, Pendergast AM. The Emerging Role of ABL Kinases in Solid Tumors. Trends Cancer. 2015;1:110-123. [PMID: 26645050 DOI: 10.1016/j.trecan.2015.07.004] [Cited by in Crossref: 40] [Cited by in F6Publishing: 50] [Article Influence: 5.7] [Reference Citation Analysis]
30 Li R, Knight JF, Park M, Pendergast AM. Abl Kinases Regulate HGF/Met Signaling Required for Epithelial Cell Scattering, Tubulogenesis and Motility. PLoS One 2015;10:e0124960. [PMID: 25946048 DOI: 10.1371/journal.pone.0124960] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
31 de Oliveira GA, Rangel LP, Costa DC, Silva JL. Misfolding, Aggregation, and Disordered Segments in c-Abl and p53 in Human Cancer. Front Oncol 2015;5:97. [PMID: 25973395 DOI: 10.3389/fonc.2015.00097] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 3.7] [Reference Citation Analysis]
32 Novak M, Leonard MK, Yang XH, Kowluru A, Belkin AM, Kaetzel DM. Metastasis suppressor NME1 regulates melanoma cell morphology, self-adhesion and motility via induction of fibronectin expression. Exp Dermatol 2015;24:455-61. [PMID: 25808322 DOI: 10.1111/exd.12697] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
33 Ha BH, Simpson MA, Koleske AJ, Boggon TJ. Structure of the ABL2/ARG kinase in complex with dasatinib. Acta Crystallogr F Struct Biol Commun 2015;71:443-8. [PMID: 25849507 DOI: 10.1107/S2053230X15004793] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
34 Markwell SM, Weed SA. Tumor and stromal-based contributions to head and neck squamous cell carcinoma invasion. Cancers (Basel) 2015;7:382-406. [PMID: 25734659 DOI: 10.3390/cancers7010382] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 3.7] [Reference Citation Analysis]
35 Ganguly SS, Li X, Miranti CK. The host microenvironment influences prostate cancer invasion, systemic spread, bone colonization, and osteoblastic metastasis. Front Oncol 2014;4:364. [PMID: 25566502 DOI: 10.3389/fonc.2014.00364] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 3.9] [Reference Citation Analysis]
36 Xing QT, Qu CM, Wang G. Overexpression of Abl2 predicts poor prognosis in hepatocellular carcinomas and is associated with cancer cell migration and invasion. Onco Targets Ther 2014;7:881-5. [PMID: 24940071 DOI: 10.2147/OTT.S62348] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
37 Blanchard Z, Mullins N, Ellipeddi P, Lage JM, McKinney S, El-Etriby R, Zhang X, Isokpehi R, Hernandez B, Elshamy WM. Geminin overexpression promotes imatinib sensitive breast cancer: a novel treatment approach for aggressive breast cancers, including a subset of triple negative. PLoS One 2014;9:e95663. [PMID: 24789045 DOI: 10.1371/journal.pone.0095663] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
38 Uitdehaag JC, de Roos JA, van Doornmalen AM, Prinsen MB, de Man J, Tanizawa Y, Kawase Y, Yoshino K, Buijsman RC, Zaman GJ. Comparison of the cancer gene targeting and biochemical selectivities of all targeted kinase inhibitors approved for clinical use. PLoS One 2014;9:e92146. [PMID: 24651269 DOI: 10.1371/journal.pone.0092146] [Cited by in Crossref: 67] [Cited by in F6Publishing: 63] [Article Influence: 8.4] [Reference Citation Analysis]
39 Wang SC. PCNA: a silent housekeeper or a potential therapeutic target? Trends Pharmacol Sci. 2014;35:178-186. [PMID: 24655521 DOI: 10.1016/j.tips.2014.02.004] [Cited by in Crossref: 148] [Cited by in F6Publishing: 164] [Article Influence: 18.5] [Reference Citation Analysis]
40 Fiore LS, Ganguly SS, Sledziona J, Cibull ML, Wang C, Richards DL, Neltner JM, Beach C, McCorkle JR, Kaetzel DM, Plattner R. c-Abl and Arg induce cathepsin-mediated lysosomal degradation of the NM23-H1 metastasis suppressor in invasive cancer. Oncogene 2014;33:4508-20. [PMID: 24096484 DOI: 10.1038/onc.2013.399] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 3.4] [Reference Citation Analysis]
41 Greuber EK, Smith-Pearson P, Wang J, Pendergast AM. Role of ABL family kinases in cancer: from leukaemia to solid tumours. Nat Rev Cancer. 2013;13:559-571. [PMID: 23842646 DOI: 10.1038/nrc3563] [Cited by in Crossref: 249] [Cited by in F6Publishing: 247] [Article Influence: 27.7] [Reference Citation Analysis]
42 Zhou S, Tang L, Wang H, Dai J, Zhang J, Shen L, Ng SW, Berkowitz RS. Overexpression of c-Abl predicts unfavorable outcome in epithelial ovarian cancer. Gynecol Oncol 2013;131:69-76. [PMID: 23820113 DOI: 10.1016/j.ygyno.2013.06.031] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
43 Zhang C, Yang C, Wang R, Jiao Y, Ampah KK, Wang X, Zeng X. c-Abl Kinase Is a Regulator of αvβ3 Integrin Mediated Melanoma A375 Cell Migration. PLoS One 2013;8:e66108. [PMID: 23805201 DOI: 10.1371/journal.pone.0066108] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
44 Yu HC, Lin CS, Tai WT, Liu CY, Shiau CW, Chen KF. Nilotinib induces autophagy in hepatocellular carcinoma through AMPK activation. J Biol Chem. 2013;288:18249-18259. [PMID: 23677989 DOI: 10.1074/jbc.m112.446385] [Cited by in Crossref: 65] [Cited by in F6Publishing: 63] [Article Influence: 7.2] [Reference Citation Analysis]
45 Xu J, Escamilla J, Mok S, David J, Priceman S, West B, Bollag G, McBride W, Wu L. CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer. Cancer Res. 2013;73:2782-2794. [PMID: 23418320 DOI: 10.1158/0008-5472.can-12-3981] [Cited by in Crossref: 330] [Cited by in F6Publishing: 335] [Article Influence: 36.7] [Reference Citation Analysis]
46 Sims JT, Ganguly SS, Bennett H, Friend JW, Tepe J, Plattner R. Imatinib reverses doxorubicin resistance by affecting activation of STAT3-dependent NF-κB and HSP27/p38/AKT pathways and by inhibiting ABCB1. PLoS One. 2013;8:e55509. [PMID: 23383209 DOI: 10.1371/journal.pone.0055509] [Cited by in Crossref: 68] [Cited by in F6Publishing: 72] [Article Influence: 7.6] [Reference Citation Analysis]
47 Sanchez-Arévalo Lobo VJ, Doni M, Verrecchia A, Sanulli S, Fagà G, Piontini A, Bianchi M, Conacci-Sorrell M, Mazzarol G, Peg V, Losa JH, Ronchi P, Ponzoni M, Eisenman RN, Doglioni C, Amati B. Dual regulation of Myc by Abl. Oncogene 2013;32:5261-71. [PMID: 23318434 DOI: 10.1038/onc.2012.621] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
48 Hossain S, Dubielecka PM, Sikorski AF, Birge RB, Kotula L. Crk and ABI1: binary molecular switches that regulate abl tyrosine kinase and signaling to the cytoskeleton. Genes Cancer 2012;3:402-13. [PMID: 23226578 DOI: 10.1177/1947601912460051] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
49 Ganguly SS, Plattner R. Activation of abl family kinases in solid tumors. Genes Cancer 2012;3:414-25. [PMID: 23226579 DOI: 10.1177/1947601912458586] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 3.2] [Reference Citation Analysis]
50 Hayes KE, Walk EL, Ammer AG, Kelley LC, Martin KH, Weed SA. Ableson kinases negatively regulate invadopodia function and invasion in head and neck squamous cell carcinoma by inhibiting an HB-EGF autocrine loop. Oncogene 2013;32:4766-77. [PMID: 23146907 DOI: 10.1038/onc.2012.513] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 3.0] [Reference Citation Analysis]
51 Furlan A, Lamballe F, Stagni V, Hussain A, Richelme S, Prodosmo A, Moumen A, Brun C, Del Barco Barrantes I, Arthur JS, Koleske AJ, Nebreda AR, Barilà D, Maina F. Met acts through Abl to regulate p53 transcriptional outcomes and cell survival in the developing liver. J Hepatol 2012;57:1292-8. [PMID: 22889954 DOI: 10.1016/j.jhep.2012.07.044] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
52 Gil-Henn H, Patsialou A, Wang Y, Warren MS, Condeelis JS, Koleske AJ. Arg/Abl2 promotes invasion and attenuates proliferation of breast cancer in vivo. Oncogene 2013;32:2622-30. [PMID: 22777352 DOI: 10.1038/onc.2012.284] [Cited by in Crossref: 79] [Cited by in F6Publishing: 81] [Article Influence: 7.9] [Reference Citation Analysis]